March 13, 2006

Vical has announced that its licensee, sanofi-aventis, has reported encouraging data from a Phase IIb trial of its angiogenesis product candidate NV1FGF, using Vical's DNA-delivery technology. Sanofi-aventis has also disclosed plans to advance to Phase III testing of the product candidate in the fourth quarter of 2006.

NV1FGF, also called XRP0038, contains DNA-encoding Fibroblast Growth Factor 1, a human protein that promotes the growth of blood vessels. When delivered by injection into a muscle in an area of restricted blood flow, NV1FGF is designed to be taken up by muscle cells and cause those cells to express the FGF protein, with the goal of promoting blood vessel growth near the injection site.